The effectiveness of this F-1 allows the selling shareholder to begin selling into the market immediately. With ~2M ADSs registered and the stock trading at $2.56, this represents a meaningful overhang relative to likely daily volume. Monitor for any Form 4 filings or prospectus supplements indicating actual sales have commenced.
Price Chart
Executive Summary
The SEC declared BioLineRx's F-1 registration statement effective on October 2, 2026, enabling the resale of up to 2,023,382 ADSs by a selling shareholder upon exercise of warrants issued in an August 2026 private placement. The company will not receive any proceeds from the resale, but may receive cash exercise proceeds from the warrants. This creates a near-term overhang of up to ~2M ADSs (representing ~1.2B ordinary shares) that can be sold into the market.
Key Facts
- Effectiveness date: October 2, 2026
- Registration covers resale of up to 2,023,382 ADSs by a single selling shareholder
- Each ADS represents 600 ordinary shares (post January 2025 ratio change)
- Warrants were originally issued in an August 2026 private placement
- Company receives no proceeds from the resale; only cash exercise proceeds if warrants are exercised on a cash basis
- ADSs trade on Nasdaq under BLRX; closing price on Sept 23, 2026 was $2.56 per ADS
- Ordinary shares trade on TASE under BLRX; last reported price on Sept 23, 2026 was NIS 0.013 ($0.0043) per share
Financial Impact
Up to 2,023,382 ADSs (each representing 600 ordinary shares) registered for resale; at the $2.56 reference price, the registered ADSs represent approximately $5.2 million in potential selling pressure
Risk Factors
- Potential near-term selling pressure as the selling shareholder can now resell registered ADSs
- Dilution from warrant exercise could further increase share count if exercised on a cash basis
- Low ordinary share price on TASE (NIS 0.013) suggests significant existing dilution
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003144 |
| Document: 9999999995-26-003144-index.html | 9999999995-26-003144 |
| Document: 9999999995-26-003144.txt | 9999999995-26-003144 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 6-K | $2.04 | awaiting T+20 | — | $2.01 (−1.47%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.01 (+13.36%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.01 (−17.28%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.01 (−21.77%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.01 (−33.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers